Skip to Content
  • Previous Rank65
  • Revenues ($M)42,237
  • Revenue Percent Change-4.1%
  • Profits ($M)11,920
  • Profits Percent Change170.7%
  • Market Value (as of March 31, 2015)163,139

The pharma company’s revenues have slipped in recent years due to patent expirations, but Merck, whose diabetes drugs and Measles vaccine did well in 2014, freshened up its aging portfolio with a handful of newly approved drugs. The drugmaker has narrowed its focus to a few key therapeutic areas and is chucking the rest–notably, its OTC business, which it sold to Bayer for $14.2 billion last May. The company has since acquired the biotech Idenix, to bulk up its efforts in Hepatitis C, and Cubist Pharmaceuticals, a company developing antibiotics against superbugs. But it’s Merck’s bet on immuno-oncology meds—promising and pricey treatment for a range of cancers—that has investors most excited.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Info

CEO
Kenneth C. Frazier
Industry
Pharmaceuticals
Sector
Health Care
HQ Location
Kenilworth, NJ
Websitehttp://www.merck.com
Years on List21

Key Financials (last fiscal year)

$ millions% change
Revenues ($M)42,237-4.1%
Profits ($M)11,920170.7%
Total Stockholder Equity48,647-
Employees70,000-
Market Value (as of March 31, 2015)163,139-

Profit Ratios

Profit as % of Revenues28.2%
Profits as % of Assets12.1%
Profits as % of Stockholder Equity24.5%

Earnings Per Share (last fiscal year)

Earnings Per Share ($)4.07
EPS % Change (from 2013)176.9%
EPS % Change (5 year annual rate)-6.3%
EPS % Change (10 year annual rate)4.5%

Total Return

Total Return to Investors (2014)17.1%
Total Return to Investors (5 year, annualized)13.6%
Total Return to Investors (10 year, annualized)10.3%